Police & Firemen s Retirement System of New Jersey Purchases 11,012 Shares of AbbVie Inc. $ABBV

Police & Firemen s Retirement System of New Jersey grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 269,019 shares of the company’s stock after acquiring an additional 11,012 shares during the quarter. AbbVie comprises approximately 0.5% of Police & Firemen s Retirement System of New Jersey’s holdings, making the stock its 24th largest holding. Police & Firemen s Retirement System of New Jersey’s holdings in AbbVie were worth $49,935,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie in the 2nd quarter worth about $25,000. TD Capital Management LLC increased its stake in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares during the last quarter. Spurstone Advisory Services LLC bought a new stake in AbbVie during the second quarter worth approximately $28,000. Cypress Capital Management LLC WY purchased a new stake in AbbVie during the first quarter valued at approximately $35,000. Finally, Bear Mountain Capital Inc. lifted its stake in shares of AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Wells Fargo & Company boosted their target price on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Daiwa Capital Markets raised shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective for the company in a research note on Thursday, August 7th. BMO Capital Markets increased their target price on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Evercore ISI lifted their price target on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Finally, Wall Street Zen raised shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $236.57.

AbbVie Stock Performance

AbbVie stock opened at $233.42 on Thursday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company has a market capitalization of $412.54 billion, a PE ratio of 111.15, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a 50 day moving average price of $224.10 and a 200-day moving average price of $203.43. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the business posted $3.00 EPS. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.